AstraZeneca's Tezspire gets EU nod for nasal polyps

TL;DR

EU panel backs AstraZeneca's Tezspire for nasal polyps - big win for respiratory franchise!

AI Summary

AstraZeneca PLC announced on September 22, 2025, that their drug Tezspire has been recommended for approval in the European Union for the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). This recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is a significant step towards making Tezspire available to patients in the EU for this indication.

Why It Matters

This European approval could expand the market for Tezspire and provide a new treatment option for patients suffering from severe uncontrolled CRSwNP, potentially impacting AstraZeneca's revenue and market share in the respiratory disease sector.

Risk Assessment

Risk Level: low — This filing is an informational report of a positive regulatory recommendation, not a financial event with immediate negative implications.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report and developer of Tezspire
• Tezspire (drug) — The drug recommended for approval
• European Union (location) — Region where approval is sought
• CRSwNP (medical_condition) — Indication for Tezspire
• CHMP (organization) — Committee that made the recommendation
• September 22, 2025 (date) — Date of the filing and recommendation

FAQ

From the Filing

0001654954-25-010967.txt : 20250922 0001654954-25-010967.hdr.sgml : 20250922 20250922073928 ACCESSION NUMBER: 0001654954-25-010967 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250922 FILED AS OF DATE: 20250922 DATE AS OF CHANGE: 20250922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251328433 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a2198a.htm TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP a2198a FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of September   2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________             AstraZeneca PLC   INDEX TO EXHIBITS     1. Tezspire Recommended for Approval in EU for CRSwNP       22 September 2025   Tezspire   recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps   Recommendation based on WAYPOINT Phase III trial results showing Tezspire reduced nasal polyp severity and nasal congestion, nearly eliminated the need for surgery and significantly reduced systemic corticosteroid use vs. placebo   AstraZeneca and Amgen's  Tezspire  (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).   The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the  WAYPOINT  Phase III trial, which were presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress and simultaneously published in  The New England Journal of Medicine . 1,2   In the WAYPOINT trial,  Tezspire  demonstrated a statistically significant and clinically meaningful reduction in nasal polyp severity, as measured by the co-primary endpoints; Nasal Polyp Score (NPS) by -2.08 (95% CI: -2.40, -1.76; p<0.001) and nasal congestion (measured by participant-reported Nasal Congestion Score [NCS]) by -1.04 (95% CI: -1.21, -0.87; p<0.001) at week 52 compared to plac